Shattuck Labs, Inc.

Shattuck Labs, Inc.

$1.54
0.07 (4.76%)
NASDAQ
USD, US
Biotechnology

STTK Price Chart

Basic
Market Cap$177.55M
Price$1.54
52 Week Range1.33-11.76
Beta1.74
Margins
Gross Profit Margin4.53%
Operating Profit Margin-2195.81%
Net Profit Margin-2067.99%
Valuation (TTM)
P/E Ratio-0.92
Price to Sales Ratio17.82
Price to Book Ratio0.71
PEG Ratio-0.22

Industry

Biotechnology

Sector

Healthcare

Full-Time Employees

75

IPO Date

2020-10-09T00:00:00.000Z

Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Phone

512 900 4690

Address

500 West 5th Street, Austin, TX, 78703, US

CIK

0001680367